JD Health International Inc. held its Annual General Meeting on 29 June 2026, with all tabled resolutions gaining solid backing via poll voting.

• Share capital context The company had 3.21 billion issued shares; after excluding 20.94 million repurchased shares pending cancellation and 27.68 million scheme-related shares not entitled to vote, 3.16 billion shares carried voting rights at the meeting.

• Financial statements and director remuneration The FY-2025 audited consolidated financial statements were adopted with 99.97% approval (2.70 billion votes in favour). Director remuneration was authorised with 99.83% support (2.70 billion votes).

• Board composition confirmed Re-elections recorded strong majorities: – Executive Director Dong Cao: 99.96% approval. – Independent Non-executive Director Ling Li: 99.99% approval. – Non-executive Director Richard Qiangdong Liu: 95.04% approval, marking the lowest—but still decisive—support level among board nominees.

• Auditor re-appointment Deloitte Touche Tohmatsu was re-appointed as external auditor through a 93.91% favourable vote (2.54 billion votes).

• Capital management mandates 1. General issuance mandate: 87.31% approval, authorising the board to issue, allot or deal in shares. 2. Share repurchase mandate: 99.94% approval. 3. Extension of issuance mandate (adding repurchased shares to the limit): 88.34% approval.

All resolutions required a simple majority and were duly passed. Computershare Hong Kong Investor Services Limited acted as scrutineer.

Directors Dong Cao, Ling Li, Jiyu Zhang, Xingyao Chen, Ying Wu and George Lau attended the AGM; Richard Qiangdong Liu was absent due to other business commitments.